{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T04:05:28Z","timestamp":1788408328436,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,4]]},"DOI":"10.7759\/cureus.66124","type":"journal-article","created":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T13:59:11Z","timestamp":1722779951000},"source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of Bendamustine-Rituximab as Frontline Therapy for Indolent Non-Hodgkin Lymphoma: A Real-World, Single-Center, Retrospective Study"],"prefix":"10.7759","author":[{"given":"Tevy","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Nicolas","family":"Champagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Samuel","family":"Boudreault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-01018-6","article-title":"How we treat mature B-cell neoplasms (indolent B-cell lymphomas)","volume":"14","author":"Lumish M","year":"2021","unstructured":"Lumish M, Falchi L, Imber BS, Scordo M, von Keudell G, Joffe E. How we treat mature B-cell neoplasms (indolent B-cell lymphomas). J Hematol Oncol. 2021, 14:5. 10.1186\/s13045-020-01018-6","journal-title":"J Hematol Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Brice P","year":"1997","unstructured":"Brice P, Bastion Y, Lepage E, et al.. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1997, 15:1110-7. 10.1200\/JCO.1997.15.3.1110","journal-title":"J Clin Oncol"},{"key":"ref3","article-title":"Current trends in diagnosis and management of follicular lymphoma","volume":"12","author":"Gupta G","year":"2022","unstructured":"Gupta G, Garg V, Mallick S, Gogia A. Current trends in diagnosis and management of follicular lymphoma. Am J Blood Res. 2022, 12:105-24.","journal-title":"Am J Blood Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus R","year":"2005","unstructured":"Marcus R, Imrie K, Belch A, et al.. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005, 105:1417-23. 10.1182\/blood-2004-08-3175","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-2-14","article-title":"R-CHOP versus R-CVP in the treatment of follicular lymphoma: a meta-analysis and critical appraisal of current literature","volume":"2","author":"Siddhartha G","year":"2009","unstructured":"Siddhartha G, Vijay P. R-CHOP versus R-CVP in the treatment of follicular lymphoma: a meta-analysis and critical appraisal of current literature. J Hematol Oncol. 2009, 2:14. 10.1186\/1756-8722-2-14","journal-title":"J Hematol Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel MJ","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyeret G, et al.. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013, 381:1203-10. 10.1016\/S0140-6736(12)61763-2","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn IW","year":"2014","unstructured":"Flinn IW, van der Jagt R, Kahl BS, et al.. Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014, 123:2944-52. 10.1182\/blood-2013-11-531327","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus R","year":"2017","unstructured":"Marcus R, Davies A, Ando K, et al.. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017, 377:1331-44. 10.1056\/NEJMoa1614598","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles G","year":"2011","unstructured":"Salles G, Seymour JF, Offner F, et al.. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011, 377:42-51. 10.1016\/S0140-6736(10)62175-7","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01073","article-title":"Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study","volume":"37","author":"Bachy E","year":"2019","unstructured":"Bachy E, Seymour JF, Feugier P, et al.. Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study. J Clin Oncol. 2019, 37:2815-24. 10.1200\/JCO.19.01073","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15720","article-title":"Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma","volume":"184","author":"Hill BT","year":"2019","unstructured":"Hill BT, Nastoupil L, Winter AM, et al.. Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma. Br J Haematol. 2019, 184:524-35. 10.1111\/bjh.15720","journal-title":"Br J Haematol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson BD","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014, 32:3059-68. 10.1200\/JCO.2013.54.8800","journal-title":"J Clin Oncol"},{"key":"ref13","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. (2017). https.\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo C","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL, et al.. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015, 33:2516-22. 10.1200\/JCO.2014.59.7534","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-179228","article-title":"Retrospective analysis of the impact of bendamustine dose reduction and chemotherapy on the outcomes of follicular lymphoma","volume":"142","author":"Koba Y","year":"2023","unstructured":"Koba Y, Bandai K, Hiranuma N, Fujiwara K, Kawata T, Tamekane A, Watanabe M. Retrospective analysis of the impact of bendamustine dose reduction and chemotherapy on the outcomes of follicular lymphoma. Blood. 2023, 142:6167. 10.1182\/blood-2023-179228","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34412","article-title":"Bendamustine and rituximab is well-tolerated and efficient in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma in elderly: a single center observational study","volume":"152","author":"Kotchetkov R","year":"2023","unstructured":"Kotchetkov R, Drennan IR, Susman D, DiMaria E, Gerard L, Nay D, Prica A. Bendamustine and rituximab is well-tolerated and efficient in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma in elderly: a single center observational study. Int J Cancer. 2023, 152:1884-93. 10.1002\/ijc.34412","journal-title":"Int J Cancer"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp090328","article-title":"Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia","volume":"67","author":"Elefante A","year":"2010","unstructured":"Elefante A, Czuczman MS. Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Am J Health Syst Pharm. 2010, 67:713-23. 10.2146\/ajhp090328","journal-title":"Am J Health Syst Pharm"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3468-8","article-title":"Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience","volume":"25","author":"Cerchione C","year":"2017","unstructured":"Cerchione C, De Renzo A, Di Perna M, et al.. Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience. Support Care Cancer. 2017, 25:839-45. 10.1007\/s00520-016-3468-8","journal-title":"Support Care Cancer"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24921","article-title":"Late infections and secondary malignancies after bendamustine\/rituximab or RCHOP\/RCVP chemotherapy for B-cell lymphomas","volume":"93","author":"Olszewski AJ","year":"2018","unstructured":"Olszewski AJ, Reagan JL, Castillo JJ. Late infections and secondary malignancies after bendamustine\/rituximab or RCHOP\/RCVP chemotherapy for B-cell lymphomas. Am J Hematol. 2018, 93:E1-3. 10.1002\/ajh.24921","journal-title":"Am J Hematol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00605","article-title":"First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study","volume":"37","author":"Flinn IW","year":"2019","unstructured":"Flinn IW, van der Jagt R, Kahl B, et al.. First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. J Clin Oncol. 2019, 37:984-91. 10.1200\/JCO.18.00605","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.278766","article-title":"Time for an individualized approach to first-line management of follicular lymphoma","volume":"107","author":"Cartron G","year":"2022","unstructured":"Cartron G, Trotman J. Time for an individualized approach to first-line management of follicular lymphoma. Haematologica. 2022, 107:7-18. 10.3324\/haematol.2021.278766","journal-title":"Haematologica"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26737","article-title":"Follicular lymphoma: 2023 update on diagnosis and management","volume":"97","author":"Jacobsen E","year":"2022","unstructured":"Jacobsen E. Follicular lymphoma: 2023 update on diagnosis and management. Am J Hematol. 2022, 97:1638-51. 10.1002\/ajh.26737","journal-title":"Am J Hematol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser F","year":"2018","unstructured":"Morschhauser F, Fowler NH, Feugier P, et al.. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med. 2018, 379:934-47. 10.1056\/NEJMoa1805104","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.4786","article-title":"Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35\/98","volume":"28","author":"Martinelli G","year":"2010","unstructured":"Martinelli G, Schmitz SF, Utiger U, et al.. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35\/98. J Clin Oncol. 2010, 28:4480-4. 10.1200\/JCO.2010.28.4786","journal-title":"J Clin Oncol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00262","article-title":"Chemotherapy-free initial treatment of advanced indolent lymphoma has durable effect with low toxicity: results from two Nordic Lymphoma Group trials with more than 10 years of follow-up","volume":"36","author":"Lockmer S","year":"2018","unstructured":"Lockmer S, \u00d8stenstad B, Hagberg H, et al.. Chemotherapy-free initial treatment of advanced indolent lymphoma has durable effect with low toxicity: results from two Nordic Lymphoma Group trials with more than 10 years of follow-up. J Clin Oncol. 2018, 36:JCO1800262. 10.1200\/JCO.18.00262","journal-title":"J Clin Oncol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020000156","article-title":"How do I sequence therapy for follicular lymphoma?","volume":"2020","author":"Salles G","year":"2020","unstructured":"Salles G. How do I sequence therapy for follicular lymphoma?. Hematology Am Soc Hematol Educ Program. 2020, 2020:287-94. 10.1182\/hematology.2020000156","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv376","article-title":"Life expectancy of young adults with follicular lymphoma","volume":"26","author":"Conconi A","year":"2015","unstructured":"Conconi A, Lobetti-Bodoni C, Montoto S, et al.. Life expectancy of young adults with follicular lymphoma. Ann Oncol. 2015, 26:2317-22. 10.1093\/annonc\/mdv376","journal-title":"Ann Oncol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson CA","year":"2022","unstructured":"Jacobson CA, Chavez JC, Sehgal AR, et al.. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022, 23:91-103. 10.1016\/S1470-2045(21)00591-X","journal-title":"Lancet Oncol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler NH","year":"2022","unstructured":"Fowler NH, Dickinson M, Dreyling M, et al.. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022, 28:325-32. 10.1038\/s41591-021-01622-0","journal-title":"Nat Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01097","article-title":"Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy","volume":"42","author":"Iacoboni G","year":"2024","unstructured":"Iacoboni G, Navarro V, Mart\u00edn-L\u00f3pez A\u00c1, et al.. Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy. J Clin Oncol. 2024, 42:205-17. 10.1200\/JCO.23.01097","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/262657-efficacy-and-safety-of-bendamustine-rituximab-as-frontline-therapy-for-indolent-non-hodgkin-lymphoma-a-real-world-single-center-retrospective-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T13:59:18Z","timestamp":1722779958000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/262657-efficacy-and-safety-of-bendamustine-rituximab-as-frontline-therapy-for-indolent-non-hodgkin-lymphoma-a-real-world-single-center-retrospective-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,4]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.66124","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,4]]}}}